Protocol Ledger

NCT06776783 · Phase III · RECRUITING

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

Interventional Phase III clinical trial protocol NCT06776783 sponsored by Aerogen Pharma Limited in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-24 Enrollment: 520 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06776783
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)520 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06776783
Protocol FieldVerified Registry Value
NCT IdentifierNCT06776783
Consolidated Lead SponsorAerogen Pharma Limited
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment520 participants (ESTIMATED)
Registered Start Date2025-09-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06776783
Hospital Research SiteLocationSite Profile
University of Arkansas for Medical SciencesLittle Rock, AROpen Hospital Dossier ->
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
Tufts Medical CenterBoston, MAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI